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Background: The human genome contains multiple LTR elements including human endogenous retroviruses (HERVs)
that together account for approximately 8–9% of the genomic DNA. At least 40 different HERV groups have been
assigned to three major HERV classes on the basis of their homologies to exogenous retroviruses. Although most
HERVs are silenced by a variety of genetic and epigenetic mechanisms, they may be reactivated by environmental
stimuli such as exogenous viruses and thus may contribute to pathogenic conditions. The objective of this study was
to perform an in-depth analysis of the influence of HIV-1 infection on HERV activity in different cell types.
Results: A retrovirus-specific microarray that covers major HERV groups from all three classes was used to analyze HERV
transcription patterns in three persistently HIV-1 infected cell lines of different cellular origins and in their uninfected
counterparts. All three persistently infected cell lines showed increased transcription of multiple class I and II HERV
groups. Up-regulated transcription of five HERV taxa (HERV-E, HERV-T, HERV-K (HML-10) and two ERV9 subgroups) was
confirmed by quantitative reverse transcriptase PCR analysis and could be reversed by knock-down of HIV-1 expression
with HIV-1-specific siRNAs. Cells infected de novo by HIV-1 showed stronger transcriptional up-regulation of the HERV-K
(HML-2) group than persistently infected cells of the same origin. Analysis of transcripts from individual members of this
group revealed up-regulation of predominantly two proviral loci (ERVK-7 and ERVK-15) on chromosomes 1q22 and
7q34 in persistently infected KE37.1 cells, as well as in de novo HIV-1 infected LC5 cells, while only one single HML-2
locus (ERV-K6) on chromosome 7p22.1 was activated in persistently infected LC5 cells.
Conclusions: Our results demonstrate that HIV-1 can alter HERV transcription patterns of infected cells and indicate a
correlation between activation of HERV elements and the level of HIV-1 production. Moreover, our results suggest that
the effects of HIV-1 on HERV activity may be far more extensive and complex than anticipated from initial studies with
clinical material.
Keywords: Human endogenous retroviruses (HERV), Human immunodeficiency virus 1 (HIV-1), HERV transcription
profiling, Retrovirus-specific microarray, siRNA* Correspondence: leib@helmholtz-muenchen.de
1Institute of Virology, Helmholtz Zentrum München, German Research Center
for Environmental Health, Neuherberg, Germany
3Department of Hematology and Oncology, University Hospital Mannheim,
University of Heidelberg, Mannheim, Germany
Full list of author information is available at the end of the article
© 2015 Vincendeau et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Vincendeau et al. Retrovirology  (2015) 12:27 Page 2 of 17Background
Approximately 8–9% of the human genome is composed
of endogenous retroviral elements (HERVs). Endogenous
retroviruses are found in all phyla and homologues of
most HERVs are present among primates, which repre-
sents 70 million years of evolutionary time [1]. It is hy-
pothesized that during the course of primate evolution,
exogenous progenitors of HERVs inserted themselves
into germ-line DNA, where they expanded via reinfec-
tion and/or retrotransposition [2,3]. Full-length HERV
sequences possess a genomic organization similar to pro-
viruses of exogenous retroviruses. Therefore, HERVs were
classified in three major classes according to sequence
homologies with the polymerase (pol) gene of exogenous
animal retroviruses. Class I HERVs show sequence simi-
larities to gammaretroviruses, class II HERVs are related
to betaretroviruses and class III HERVs display a limited
similarity to spumaviruses [4]. Endogenous homologues to
lentiviruses have not been detected in the human genome.
There is no evidence to date that infectious HERVs are
produced in humans, suggesting their genetic material
replicates exclusively as part of their host’s genome. This
is in sharp contrast to many other mammals, particularly
rodents, in which the lines between endogenous and
exogenous retroviruses can become very blurred [5].
Nonetheless, in some instances only a few mutations or
recombination events would be required to reconstitute
a replication competent provirus in humans [6-8].
Some HERV elements code for individual gene products
[9,10] that could be pathogenic. For example, two small
regulatory proteins, Rec and Np9, that are encoded by the
HERV-K (HML-2) group are suspected to be involved in
some human cancers [11-13]. Other examples for poten-
tially pathogenic HERV gene products are the envelope
(Env) proteins, which possess fusogenic properties and
have been associated with several chronic diseases such as
autoimmunity and neurological disorders [14-16].
Most HERVs have been silenced by mutations and/or
epigenetic control e.g. methylation of DNA or chromatin
modifications. However, they may be reactivated by envir-
onmental stimuli such as radiation and chemicals [17-19]
or by infectious agents such as exogenous viruses [20-24].
Epstein-Barr virus (EBV) and human herpes virus 6
(HHV-6), for example, have been shown to transactivate
expression of a potential HERV-K18 encoded superantigen
that stimulates T-cell activation [23,25-29]. This process
might be crucial for the establishment of long-term infec-
tion by EBV and HHV-6 and play a role in the deve-
lopment of associated diseases. Similarly, expression of
HERV-W Env protein has been proposed to be induced by
Herpesviridae in patients with multiple sclerosis (MS) and
hypothesized to be linked with MS pathogenesis [22]. We
have recently shown that human cytomegalovirus (HCMV)
activates a number of HERV groups including HERV-K(HML-2) [30]. Because of the association with a multitude
of complex diseases, a better understanding of the influ-
ence of exogenous viruses on the expression of HERVs in
human cells is necessary in various pathogenic contexts.
Lentiviruses and HERVs share many structural and func-
tional features like the LTR as key director and regulator of
transcription. The potential complementation of HERV
and HIV encoded proteins provides additional interaction
points reviewed in [31]. For example, regulatory HIV-1 Rev
protein has been shown to substitute for HERV-K (HML-
2) Rec (cORF) protein in functional assays [32-34]. On the
other hand, HIV-1 infection may compromise intracellular
defense mechanisms normally down-regulating HERV
activity [35,36]. Data from several reports support an in-
fluence of HIV-1 infection on HERV expression. Thus,
antibodies against Env proteins of HERV-K102, a member
of the HERV-K (HML-2) group, have been found to occur
with higher frequency in HIV-1 viraemic patients than in
healthy individuals [37]. Another study identified T cells
responding to HERV epitopes of various HERV groups in
HIV-1 infected individuals [38-41]. Furthermore, HERV-K
(HML-2) RNA was reported in peripheral blood mono-
nuclear cells (PBMCs) or plasma of HIV-1 infected
patients [42-45].
To gain more insight into the influence of HIV-1
infection on HERV expression on the cellular level, we
investigated HERV transcription patterns in persistently
HIV-1 infected cell lines with different HIV-1 production
levels, in cells infected de novo with HIV-1 and in the cor-
responding uninfected cells. Simultaneous profiling of a
large number of HERVs was enabled using a retrovirus-
specific DNA chip based on a conserved region within
the pol gene that covers major HERV groups from all
three classes [46,47]. We hypothesized that, if a direct link
between HIV-1 and HERV transcription exists, removal of
the stimulus (i.e. HIV-1 gene products) should result in a
corresponding decrease of the stimulated HERV transcrip-
tion. Thus, we used siRNAs directed against HIV-1 tran-
scripts as well as a cellular inhibitor of HIV Rev activity to
observe their effects on HERV transcription. Furthermore,
we identified transcribed HERV-K (HML-2) loci with dif-
ferential activity in persistently and in de novo HIV-1
infected cells. Our data demonstrates up-regulation of sev-
eral class I and class II HERV groups and links HERV
transcription with expression and production of HIV-1 in
persistently infected cells.
Results
HERV transcription profiles of HIV-1 infected human cell
lines with different levels of HIV-1 production
The present study was initiated to explore a possible influ-
ence of HIV-1 infection on the transcriptional activities of
various HERV groups in HIV-1 infected cells. To this end
we used a retrovirus-specific, pol-based microarray that
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HERVs and discriminates between 49 HERV subgroups
derived from 20 prominent groups representing al three
HERV classes [46-48].
First we examined three persistently HIV-1 infected
cell lines, TH4-7-5, LC5-HIV and KE37.1-IIIB. All per-
sistently infected cell lines contain infectious proviruses.
The provirus copy numbers are shown in Figure 1D. We
chose these cell lines because they differ in their HIV
productivity [49] and thus could be used to determine a
possible correlation between levels of HIV-1 production
and HERV transcription. The corresponding uninfected
cell lines 85HG66 (astrocytes), LC5 (a derivative of HeLa
cells [50]) and KE37.1 (T-lymphoma cells), respectively,
were used as controls.
The infected cell lines were analyzed for their ability
to produce viral proteins by measuring levels of the
HIV-1 capsid protein Gag p24 in samples of cell lysates
(intracellular p24) and in culture supernatants (extracel-
lular p24) harvested after 24 hours virus production.
The three cell lines TH4-7-5, LC5-HIV and KE37.1-IIIBFigure 1 Productivity of different persistently HIV-1 infected human c
TH4-7-5, KE37.1-IIIB and LC5-HIV. (B) Extracellular p24-production in the in
p24 antigen in infected cells and in the supernatant was performed as de
persistently infected cell lines TH4-7-5, KE37.1-IIIB and LC5-HIV. (D) Proviru
LC5-HIV measured with quantitative PCR. Absolute quantification of HIV pdiffered clearly in their p24 production levels (Figure 1A).
TH4-7-5 cells exhibited the lowest p24 production. The
LC5-HIV and KE37.1-IIIB cells produced approximately
10 to 40 fold higher levels of intracellular p24 than the
TH4-7-5 cells. In agreement, release of p24 protein was
detected only in culture supernatants of LC5-HIV and
KE37.1-IIIB cells, but not in supernatants of TH4-7-5
cells (Figure 1B). Using specific PCR primers, we could
further show that the infected cell lines produce specific
HIV-1 transcripts, whereas the uninfected control cells do
not (Figure 1C). This data correlates with the p24 protein
levels.
To get a general overview of HERV expression in
HIV-1 infected and uninfected cells a retrovirus specific
microarray was used. Microarray analysis was conducted in
triplicates according to a standardized chip hybridization
protocol [46,48,51]. Three house keeping genes served as
internal controls for RNA quality. The HIV-1 capture probe
served as a control to show that all infected cell lines
(KE37.1-IIIB, LC5-HIV, TH4-7-5) are HIV-1 positive and
all uninfected cells (KE37.1, LC5, 85HG66) are HIV-1ell lines. (A) Intracellular p24-production in the infected cell lines
fected cell lines TH4-7-5, KE37.1-IIIB and LC5-HIV. Quantification of
scribed [82] using a p24 ELISA. (C) HIV-1 transcript levels in the
s copy numbers of the infected cell lines TH4-7-5, KE37.1-IIIB and
roviral copies was performed as described in [82].
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HERV pol (RT) sequences derived from 20 major groups of
class I (gammaretrovirus-related), class II (betaretrovirus-
related), and class III (spumaretrovirus-related) HERVs
[46,47]. Depending on deletions within the targeted pol
sequence and on sequence variability, the microarray may
detect about half up to two third of the elements belonging
to a HERV group. The 49 sequences spotted on the chip
represent HERV subgroups that are defined by about
20% sequence divergence from each other within the
analyzed pol region [4,52]. For microarray analysis, con-
ditions were used that require at least 80% sequence
identity for hybridization [48,53]. Thus, each HERV
subgroup may consist of about 10 to 100 closely related
proviral loci with sufficient sequence similarity that in-
dividual elements cannot be distinguished. Depending on
the size of a subgroup and its transcriptional activity, one
or more transcribed loci may hybridize to one spot of
the microarray, and in a few cases cross-hybridization
between related subgroups is observed. False positive
signals cannot be ruled out completely, but were mini-
mized by amplifying the hybridization probe with HERV-
specific primers before microarray hybridization. Despite
of the limitations this method allows a fast and compre-
hensive screening of overall HERV activity in a cell type.Figure 2 HERV transcription profiles of HIV-1 infected cell lines exam
used for image visualization. The house keeping genes ubiquitin, glycerinalde
phosphoribosyltransferase (HPRT) served as a quality control and internal stan
control and to demonstrate HIV-1 infection. HERVs are grouped in class I, II an
microarray can represent multiple HERV proviruses of one multicopy HERV s
cannot be distinguished. (A) Comparison of persistently HIV-1 infected cell lin
subgroups are indicated by red letters. HERV subgroups marked with a g
of de novo HIV-1 infected LC5-RIC cells with uninfected cells.Figure 2A displays an alignment of the hybridization pat-
terns obtained with RNA from persistently HIV-1 infected
cell lines compared to the corresponding uninfected cells.
Members of 7 HERV groups, HERV-T, HERV-E, HERV-W,
ERV-9, HML-3, HML-4 and HML-10, belonging to class I
and II HERVs were found up-regulated in virus producing
cells when compared to uninfected control cells (marked in
red in Figure 2A). The more ancient class III HERV ele-
ments remained unaffected in all cell lines. A significant
increase of HERV-K (HML-2) transcripts, previously asso-
ciated with HIV-1 infection in patients [38,42] was not
detected in any of the persistently infected cell lines by
microarray analysis. Up-regulation of HERV-F, HML-1
and HML-5 was observed only in the HIV-1 infected
lymphocytic cell line KE37.1-IIIB. Comparison of the HERV
transcription profiles of the three infected cell lines with
each other suggests that the up-regulation of HERV
transcription may be connected to HIV-1 production
levels.
To analyze the influence of de novo HIV-1 infection
and to determine, whether HERV transcription patterns
in de novo and persistently infected cells differ, we in-
fected LC5 cells expressing a fluorescent HIV reporter
(LC5-RIC) with the HIV-1 patient isolate P-891 de-
scribed in [54,55]. The de novo HIV-1 infected cellsined by a retrovirus-specific microarray. False color mapping was
hyde-3-phosphate-dehydrogenase (GAPDH) and hypoxanthine-guanine
dard. HIV-1 oligonucleotides are also spotted on the chip as a positive
d III elements. It should be noted that each positive spot on the
ubgroup with sufficient sequence similarity that individual elements
es with the corresponding uninfected cell lines. Up-regulated HERV
reen asterisk were additionally analyzed by qRT-PCR. (B) Comparison
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that of persistently infected LC5 cells. Both, de novo and per-
sistently infected cells displayed increased transcription of
HERV-E and ERV9 subgroups (Figure 2A and B). However,
enhanced transcription of members of groups HERV-T,
HERV-W, HML-4 and HML-10 was observed only in per-
sistently HIV-1 infected LC5 cells but not in de novo infected
cells. Stimulation of HERV-K (HML-3) transcription was
much weaker in de novo infected cells than in persistently
infected cells. On the other hand, the de novo HIV-1 infected
LC5-RIC cells showed a stronger activation of HERV-K
(HML-2) transcription than persistently infected cells.
Quantitative reverse transcriptase PCR confirms
differential transcription of HERVs in HIV-1 infected
and uninfected cells
Differences in the transcription levels of five representa-
tive HERV subgroups in infected and non-infected cellsFigure 3 Relative transcriptional activity of selected HERV subgroups
(B) E4-1 (group HERV-E), (C) ERV9 and Seq59 (both group ERV9) and (D) HE
Y-axis shows the x-fold relative expression of HERV-transcripts in infected c
according to [85] and normalized to RNA Polymerase II (RPII) transcript levewere subsequently analyzed by qRT-PCR using primers that
bind specifically to the pol region of the up-regulated
HERVs. These primers are located in a region of the reverse
transcriptase gene that exhibits only marginal similarity
among HERV-taxa with one primer matching the sequence
of the corresponding microarray capture probes [46,48].
Figure 3 shows the relative transcript levels of the selected
HERV taxa S71pCRTK-1 (group HERV-T), E4-1 (group
HERV-E), ERV9 and Seq59 (both group ERV9), and HERV-
KC4 (group HML-10) in the HIV-1 infected cells compared
to the uninfected control cells. Transcript levels of HERV
subgroups S71pCRTK-1 (Figure 3A) and Seq59 (Figure 3C)
were only slightly increased, whereas levels of E4-1
(Figure 3B), ERV9 (Figure 3C) and HERV-KC4 (Figure 3D)
were up to 15fold higher in HIV-1 infected cells than in
uninfected cells. This result was in agreement with the
microarray data (Figure 2A). The cell lines with high HIV-1
production (KE37.1-IIIB and LC5-HIV) demonstrated. Relative transcript levels of (A) HERV taxa S71pCRTK-1 (group HERV-T),
RV-KC4 (group HERV-K (HML-10)) were determined by qRT-PCR. The
ells referred to uninfected cells. Relative transcription was quantified
ls. Standard errors for triplicate experiments are indicated.
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7-5 cells. Thus, the results obtained by two independent
methods indicate that persistent HIV-1 infection increases
transcription of at least one member of each of 5 HERV
subgroups and that transcription levels of these HERVs
are related to HIV-1 production.
HIV-1-specific siRNAs reverse HERV up-regulation
To demonstrate that the observed alterations are indeed
associated with HIV-1 infection, we investigated if the
up-regulated HERV transcription could be reversed by
silencing of HIV-1 transcription using RNA interference
assays. The siRNAs against HIV-1 transcripts were se-
lected according to ter Brake and Berkhout [56]. An
overview of the HIV-1 transcripts, which are silenced by
the selected siRNAs is shown in Additional file 1A. The
siRNA sigag is predicted to silence all gag and pol tran-
scripts, sitat/rev all transcripts except nef, and sienv to-
gether with sinef all HIV-1 transcripts. HIV-1 contains
three major RNA splice variants coding for all proteins.
These RNAs harbor overlapping sequences making it
impossible to design siRNAs that are unique for knock-
down of individual proteins. An exception is sigag tar-
geting a gag sequence that is exclusively present in
unspliced, late mRNA. Contrary to expectation however,
sigag has been shown to down-regulate all transcripts,
possibly due to nuclear targeting of HIV-1 mRNAs prior
to splicing [56]. As control, a non-silencing siRNA was
used, and an experiment without siRNA (mock experi-
ment) was performed to control for unspecific silencing
effects by siRNAs in general and by the transfection re-
agent, respectively. The capacity of the siRNAs to inhibit
HIV-1 production was tested in LC5-HIV cells. All HIV-
1-specific siRNAs efficiently decreased levels of full-
length HIV-1 transcripts (Additional file 1B) and of the
Gag p24 protein (data not shown) 72 hours after siRNA
transfection. The knock-down effect of these siRNAs on
spliced HIV-1 transcript was not tested in this study, but
has been demonstrated previously [56].
The five HERV taxa S71pCRTK-1, E4-1, ERV-9, Seq59
and HERV-KC4 activated by HIV-1 in previous experi-
ments were analyzed by qRT-PCR 72 hours after trans-
fection of the siRNAs. Figure 4 shows the relative
transcription levels of the HERV subgroups in the HIV-1
infected HeLa cells (LC5-HIV) transfected with specific
siRNAs against gag, rev, nef and env compared to control
cells transfected with non-silencing siRNA. Knockdown of
HIV-1 in LC5-HIV cells resulted in a loss of HERV tran-
scription in four of five HERV subgroups (Figure 4A-D).
Only Seq59, a subgroup of ERV9 elements (Figure 4C),
appears to be only partially diminished. Thus, we can
show that knockdown of HIV-1 transcripts by RNAi re-
verses activation of specific HERV elements in infected
cells. Moreover, overexpression of a natural inhibitor ofHIV-1 production, the Rev-interacting human protein
family (Risp) [57], was found to reverse HERV activation
in HIV-1 infected LC5 cells (Additional file 2). Taken
together, our results indicate that HIV-1 infection is
associated with the activation of several taxa of class I
and class II HERVs.
Differential HERV-K (HML-2) transcription in de novo and
persistently HIV-1 infected cells
Plasma of HIV-1 infected individuals has been reported
to contain elevated levels of HERV-K (HML-2) RNA
[38,42,43]. In our microarray experiments we observed a
significant increase of HERVK (HML-2) transcription only
in de novo infected cells but not in the persistently infected
cell lines (Figure 2) suggesting that an up-regulation of
group HERV-K (HML-2) proviruses occurs preferentially
within a short period after infection. To investigate,
which HERV-K (HML-2) loci contribute to the observed
up-regulation, we cloned and sequenced HERV-K (HML-2)
gag transcripts and combined the data with qRT-PCR
analysis.
Since most commonly used primers designed to amplify
HERV-K (HML-2) co-amplify HML-3 sequences [42], we
generated new gag derived primers for qRT-PCR that are
highly specific and amplify exclusively members of the
HERV-K (HML-2) group. Analysis by qRT-PCR revealed
an approximately 8fold higher overall level of HERV-K
(HML-2) transcription in de novo HIV-1 infected LC5-
RIC cells compared to uninfected cells, whereas in
persistently infected LC5 cells the HERV-K (HML-2)
transcript level increased only about 1.8fold above the
transcript level in uninfected cells [58] (Figure 5). This
data suggests that up-regulation of HERV-K (HML-2)
proviruses may be largely restricted to de novo HIV-1
infection.
To investigate the contribution of individual proviral
loci to increased HERV-K (HML-2) transcription in HIV-
1 infected LC5-RIC cells, HERV-K (HML-2) transcripts
were amplified using the same HERV-K (HML-2)-specific
forward primer as applied for qRT-PCR in combination
with a downstream located reverse primer amplifying an
about 650 bp gag gene derived PCR product. This gag re-
gion contains a sufficient amount of nucleotide differences
to allow a clear discrimination between different proviral
loci [58].
Sequence analysis of cloned RT-PCR products derived
from uninfected cells showed predominant transcription
of a single HERV-K (HML-2) locus on chromosome
11q23.3, ERVK-20. Transcripts from this locus comprise
94% and 85% of total transcripts in LC5 and LC5-RIC
cells, respectively (Table 1, Figure 5). In addition, different
HERV-K (HML-2) loci show minor activity in both cell
lines. LC5-RIC cells are a subline of LC5 cells generated
by introducing the CD4 receptor gene and a DsRED1
Figure 4 Down-regulation of HIV-1 induced HERV activity by siRNAs targeting HIV-1 transcripts. LC5-HIV cells were treated with the
RNAiFect transfection reagent (mock), non-silencing siRNAs (sin.s.) or with siRNAs against gag (sigag), rev (sirev), nef (sinef) and env (sienv).
Relative transcript levels of (A) HERV taxa S71pCRTK-1 (group HERV-T), (B) E4-1 (group HERV-E), (C) ERV9 and Seq59 (both group ERV9) and
(D) HERV-KC4 (group HERV-K (HML-10)) were determined by qRT-PCR. The Y-axis shows the x-fold relative HERV transcript levels in LC5-HIV
cells transfected with non-silencing siRNA (sin.s) and HIV-1-specific siRNAs (sigag, sitat/rev, sinef, sienv) referred to uninfected control cells.
The data were normalized to the house-keeping gene RNA Polymerase II (RPII). Standard errors for triplicate experiments are indicated.
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transcription compared to the original LC5 cells. In per-
sistently infected LC5-HIV cells an additional HERV-K
(HML-2) provirus on chromosome 7p22.1, ERVK-6, is ac-
tivated that presumably accounts for the approximately
1.8fold increase of HERV-K (HML-2) transcription ob-
served by qRT-PCR (Figure 5). Interestingly, ERVK-6 has
intact open reading frames for all retroviral genes [59]. In
contrast to the single locus up-regulated in persistently in-
fected cells, analysis of de novo HIV-1 infected LC5-RIC
cells revealed five transcriptionally active HML-2 loci with
ERV-K15 on chromosome 7q34 comprising about 75% of
total transcripts (Table 1, Figure 5). In the T-lymphoma
cell line KE37.1 the basal HML-2 transcription pattern
(Table 2, Figure 5) resembles more that obtained with
PBMCs from healthy persons (Additional file 3) than thatof the epithelial LC5 cell line (Table 1, Figure 5). Persist-
ently infected KE37.1-IIIB cells show predominant activa-
tion of a locus on chromosome 1q22, ERK-7 (Table 2,
Figure 5). Taken together, these data demonstrate that
activation of HERV loci by HIV-1 is also cell type-specific
and may depend on epigenetic control of HERV loci
differing in various cell types.
To study the transcriptional activity of HERV-K (HML-2)
proviruses in the time course of de novo HIV-1 infection, a
subclone of the original LC5-RIC cells was infected with
HIV-1IIIB/LAI. This subclone yields a high proportion of
infected cells (Additional file 4) superseding the removal of
uninfected cells by cell sorting. Although the LC5-RIC
subclone shows a basal HERV-K (HML-2) transcription
pattern that differs from that of the original LC5 as well
as the parental LC5-RIC cells, infection with HIV-1
Figure 5 Transcriptional activity of HERV-K (HML-2) proviral loci in de novo and persistently infected cells. The Y-axis shows the x-fold
relative expression of HERV-K (HML-2) gag transcripts in infected cells referred to uninfected cells. Relative transcription was quantified according
to [85] and normalized to RPII transcript levels. HERV-K (HML-2) transcripts were amplified using gag-specific primers, cloned, sequenced and
assigned to proviral loci as described previously [58]. For each HERV-K (HML-2) locus the relative cloning frequency of cDNA is shown as percentage of
the total HERV-K (HML-2) transcription level determined by qRT-PCR.
Table 1 Differential HERV-K (HML-2) transcription in de novo and persistently infected LC5 cells
Provirusa Chromosome band Location of amplicon in genomeb Number of clones (% cloning frequency)
LC5-RIC LC5-RIC-HIVc LC5 LC5-HIVd
ERVK-7e (c1_B, K102, K50a) 1q22 153870020–153870613 - 2 (7.1) - -
ERVK-18 (c1_C, K110, K18) 1q23.3 158928993–158929564 1 (2.1) - - -
ERVK-3e,f (c3_B, K106, K68) 3q13.2 114232740–114233333 - 2 (7.1) 2 (2.2) -
ERVK-4e (c3_C, K (I)) 3q21.2 127093474–127094067 1 (2.1) 1 (3.6) 2 (2.2) -
ERVK-6e,f (c7_A, K (HML-2. HOM), K108) 7p22.1 4604296–4604932 - - - 44 (47.3)
4595814–4596407g
ERVK-14e (c7_B) 7q22.1 104179245–104179826 1 (2.1) - - -
ERVK-15 (c7_C, K (OLDAC004979)) 7q34 141101009–141101702 - 21 (75.0) 1 (1.1) -
ERVK-17e (c10_B) 10q24.2 101576433–101577026 - 2 (7.1) - -
ERVK-25e,f (c11_A, K36, K118) 11q22.1 101072651–101073244 3 (6.4) - - -
ERVK-20 (c11_B, K37) 11q23.3 118103858–118104446 40 (85.1) - 84 (94.4) 49 (52.7)
ERVK-21 (K (C12), K41, K119) 12q14.1 58728458–58729051 1 (2.1) - - -
Total number of clones 47 (100) 28 (100) 89 (100) 93 (100)
aDesignation according to [87], aliases are in parentheses.
bAccording to the March 2006 assembly (NCBI36/hg18) of the human genome sequence at the Human Genome Browser [88].
cde novo infected LC5-RIC cells.
dpersistently infected LC5 cells.
eHuman-specific HERV-K (HML-2) proviruses [89].
fPolymorphic in the human genome [89].
gThe human reference genome sequence harbors a tandem provirus [90]. Due to the lack of sufficient sequence differences the detected cDNA sequence may
stem from one or the other provirus.
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Table 2 Differential HERV-K (HML-2) transcription in the uninfected and persistently infected human T-lymphoma cell
line KE37.1
Provirusa Chromosome band Location of amplicon in genomeb Number of clones (% cloning frequency)
KE37.1 KE37.1-IIIBc
ERVK-1d,e (c1_A, K116, K4) 1p31.1 75617005–75617599 1 (2.9) -
ERVK-7d (c1_B, K102, K50a) 1q22 153870019–153870613 18 (51.4) 40 (87.0)
ERVK-18 (c1_C, K110, K18) 1q23.3 158928865–158929429 7 (20.0) -
ERVK-3d,e (c3_B, K106, K68) 3q13.2 114232739–114233333 1 (2.9) 1 (2.2)
ERVK-4d (c3_C, K (I)) 3q21.2 127093473–127094067 - -
ERVK-12 (c4_A, K5) 4q32.2 161800867–161801461 1 (2.9) -
ERVK-10d (K107, K10, c5) 5q33.3 156024233–156024827 1 (2.9) 1 (2.2)
ERVK-9e (c6_A, K109, envK4) 6q14.1 78490569–78491163 - 1 (2.2)
ERVK-15 (c7_C, K (OLDAC004979)) 7q34 141101012–141101702 6 (17.1) 2 (4.3)
ERVK-28 19q12 32827928–32828522 - 1 (2.2)
Total number of clones 35 (100%) 46 (100%)
aDesignation according to [87], aliases are in parentheses.
bAccording to the March 2006 assembly (NCBI36/hg18) of the human genome sequence at the Human Genome Browser [88].
chuman T-lymphoma cell line KE37.1 persistently infected with HIV-1IIIB/LAI.
dHuman-specific HERV-K (HML-2) proviruses [89].
ePolymorphic in the human genome [89].
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tern (Table 3, Figure 6) compared to that of the infected
parental LC5-RIC cells (Table 1, Figure 5). As in these
cells, locus ERVK-15 (7q34) shows the highest increase of
transcriptional activity. Furthermore, minor activation was
also detected for ERVK-7 (1q22), which has been shown
to be preferentially transcribed in persistently infected
KE37.1-IIIB cells. After thirteen days a decline of HERV-K
(HML-2) activity and a decrease of HIV-1 provirus copiesTable 3 Time course of HERV-K (HML-2) transcription in HIV-1
Provirusa Chromosome band Location o
ERVK-7c (c1_B, K102, K50a) 1q22 153870020–
ERVK-2 (c3_A, K11) 3p25.3 9869046–98
ERVK-3c,d (c3_B, K106, K68) 3q13.2 114232740–
ERVK-4c (c3_C, K (I)) 3q21.2 127093474–
ERVK-6c,d (c7_A, K (HML-2. HOM), K108) 7p22.1 4604296–46
4595814–45
ERVK-15 (c7_C, K (OLDAC004979)) 7q34 141101009–
ERVK-16 (c10_A, M3.8) 10p14 6913372–69
ERVK-17c (c10_B) 10q24.2 101576433–
Total number o f clones
aDesignation according to [87], aliases are in parentheses.
bAccording to the March 2006 assembly (NCBI36/hg18) of the human genome sequ
cHuman-specific HERV-K (HML-2) proviruses [89].
dPolymorphic in the human genome [89].
eThe human reference genome sequence harbors a tandem provirus [90]. Due to th
stem from one or the other provirus.was observed (Figure 6, Additional file 4), presumably due
to HIV-1 cytotoxicity.
In contrast to HERV-K (HML-2), the transcription
pattern of HERV-K (HML-3) elements detected with
HML-3 env-specific primers is similar in de novo, per-
sistently infected and in uninfected LC5 cells (Additional
file 5). Transcripts of the two prevailing HERV-K (HML-3)
loci 1q21.2 and 3q21.3 were found with cloning frequencies
in the range of 40–50% and 17–30%, respectively, ininfected LC5-RIC cells
f amplicon in genomeb Number of clones (% cloning frequency)
Day-0 Day-3 Day-13 Day-22
153870613 4 (13.3) 9 (23.1) 3 (9.4) 6 (16.7)
69639 1 (3.3) - - -
114233333 14 (46.7) 2 (5.1) 3 (9.4) 5 (13.8)
127094067 - - 2 (6.3) 5 (13.8)
04932 - - - 1 (2.8)
96407e
141101702 8 (26.7) 25 (64.1) 19 (59.4) 19 (52.8)
13968 3 (10.0) 2 (5.1) 4 (12.5) -
101577026 - 1 (2.6) 1 (3.1) -
30 (100) 39 (100) 32 (100) 36 (100)
ence at the Human Genome Browser [88].
e lack of sufficient sequence differences the detected cDNA sequence may
Figure 6 Time course of HERV-K (HML-2) in de novo HIV-1 infected LC5-RIC cells. The Y-axis shows the x-fold relative expression of HERV-K
(HML-2) gag transcripts in infected cells referred to uninfected cells. RNA was isolated from LC5-RIC cells prior to infection and from cells infected with
HIV-1IIIB/LAI at day 3, 13 and 22. Relative transcription was quantified according to [85] and normalized to RPII transcript levels. HERV-K (HML-2)
transcripts were amplified using gag-specific primers, cloned, sequenced and assigned to proviral loci as described previously [58]. For each HERV-K
(HML-2) locus the relative cloning frequency of cDNA is shown as percentage of the total HERV-K (HML-2) transcription level determined by qRT-PCR.
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fected cells. The 10 additional, minor active HERV-K
(HML-3) loci likewise showed only slight transcription
variation suggesting a less differentiated influence of
HIV-1 infection on the HERV-K (HML-3) group.
Cellular transcription factors are potential mediators of
HERV activation
To address the question, whether HERV transcription
may be up-regulated via activation of cellular transcription
factors by HIV-1 gene products, we stimulated Jurkat T-
cells by treatment with PMA/Ionomycin or by CD3/CD28
antibody ligation [60]. PMA possesses structural similarity
to diacylglycerol (DAG) and can therefore activate PKCθ
and thus NF-κB in T cells. Ionomycin induces Ca2+ influx
from intracellular Ca2+ storage compartments and there-
fore mainly influences the activation of NFAT. Crosslink-
ing of the co-stimulatory receptor CD28 and the CD3
subunits of the T cell receptor by specific primary and sec-
ondary antibodies mimics the receptor aggregation, which
under physiological conditions is induced by the T cell/
APC (antigen presenting cell) contact. This leads to acti-
vation of antigen-receptor-specific signaling cascades.
Using RetroArray analysis, the HERV activation pattern
of stimulated T-cells was compared with that obtained
after HIV-1 infection (Figure 7 and 2). A variety of HERV
groups derived from all three HERV classes was found to
be up-regulated after addition of both stimuli, PMA/Iono-
mycin and CD3/CD28 (Figure 7). Interestingly, the tran-
scription pattern in stimulated T-cells includes HERV
groups also affected in de novo (HERV-E, ERV9, HERV-K
(HML-2), HERV-K (HML-3)) as well as in persistentlyHIV-1 infected cells (HERV-T, ERV9, HERV-K (HML-3),
HERV-K (HML-4), HERV-K (HML-10)). Since IL2 is a
major target of the transcription factors induced by PMA/
Ionomycin or CD3/CD28, we verified successful stimulation
of the cells by measuring IL2 mRNA (Additional file 6). The
data suggests that major transcription factors like NF-κB,
NFAT and AP1 may be involved in the activation of at least
some HERV taxa in HIV-1 infected cells.
Discussion
Interactions between HIV and endogenous retroviruses
in infected patients may have implications for intracellular
defense mechanisms and immune response and thus may
influence the pathogenic process in many ways (reviewed
in [31]). However, the study of HIV-HERV interactions in
clinical samples from HIV-1 infected individuals is associ-
ated with several problems. A major difficulty is the lim-
ited amount of HIV-1 infected cells. Analysis of the mean
HIV-1 integrated DNA in CD4+ T-cells from individuals
under antiretroviral therapy (ART) revealed less than 1100
copies per 106 cells [61,62], indicating infection frequen-
cies < 0.2% of CD4+ T-cells. An additional problem is that
basal HERV transcription in PBMCs may mask activation
of HERVs by HIV-1. Several class I and class II HERV
groups are typically transcribed in blood cells of healthy
people [46,47,63]. In particular, transcripts of the HERV-K
(HML-2) group have been identified in PBMCs derived
from healthy individuals in several studies [64-66] in
agreement with our recent results revealing transcrip-
tion of at least 12 different HERV-K (HML-2) loci in
PBMCs from healthy donors (Additional file 3). Finally,
HERV transcription profiles may exhibit among individual
Figure 7 HERV transcription profiles of PMA/ionomycin and CD3/CD28 stimulated Jurkat T-cells. False color mapping was used for image
visualization. The house keeping gene HPRT served as a quality control and internal standard. Up-regulated HERV subgroups are indicated by
red letters.
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type investigated so far, we detected HERVs differentially
transcribed between individuals in addition to the constitu-
tively active HERV groups [51,53]. Therefore, blood sam-
ples of patients before infection with HIV-1 would be
needed for an exact and reliable assessment of HIV-1
mediated HERV activation and these are usually not
available.
To overcome these difficulties, we conceived a system-
atic study using well-defined cell culture systems consisting
of various HIV-1 infected cell lines. This approach offers a
much more homogenous genetic background for identifi-
cation of HIV-1 associated changes in HERV transcription
pattern than clinical samples and provides the appropriate
controls to evaluate expression of HERVs in the absence of
HIV-1 infection. We compared HERV transcription levels
in three different persistently infected cell lines with the re-
spective uninfected cells. In addition, we investigated the
influence of HIV-1 on HERV activity in de novo infected
cells. Activated transcription of several class I and class II
HERV groups was demonstrated by RetroArray analysis
and confirmed by qRT-PCR for five selected HERV sub-
groups (S71pCRTK-1, HERV-E (4–1), ERV-9, ERV9 Seq59
and HERV-KC4). The extent of HERV up-regulation
roughly correlated with production levels of HIV-1 struc-
tural proteins in each cell line. Importantly, activation of
HERV transcription was reversed by knock-down of HIV-1
transcript levels with HIV-1-specific siRNAs. These resultsindicate that HIV-1 infection can activate transcription of
at least five HERV subgroups.
RetroArray analysis also showed considerable activation
of HERV-K (HML-2) elements in de novo infected LC5
cells compared to persistently infected cell lines. This indi-
cates that immediate responses of HERVs to HIV-1 infec-
tion may differ from long-term effects. Since the youngest
and most active HERVs belong to the HERV-K (HML-2)
group and HERV-K (HML-2) proviruses were reported
previously to be associated with HIV-1 infection (reviewed
in [31]), we examined HERV-K (HML-2) in more detail. A
preferential activation of two loci (ERVK-7 and -15) on
chromosomes 1q22 and 7q34 was observed in de novo
infected LC5 cells, as well as in persistently infected KE37.1
cells, resulting in an 8fold to 10fold increase of overall
HERV-K (HML-2) transcription. During three weeks after
de novo infection of LC5 cells only slight alterations of the
HERV-K (HML-2) transcription pattern were observed Per-
sistently infected LC5 cells, however, showed a completely
different HERV-K (HML-2) transcription pattern. The
HERV loci activated in de novo infected cells are turned off,
but a new provirus, ERVK-6 (7p22.1), is transcribed in
addition to the ERVK-20 locus active in uninfected cells.
The distinct difference between HERV-K (HML-2) loci
transcribed in de novo and in persistently infected cells
suggests different modes of interaction with HIV-1.
In contrast to the multiple HERV-K (HML-2) loci previ-
ously reported to be activated in HIV-1 infected patients,
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ently and de novo infected LC5 cells, as well as in the
T-lymphoma cell line KE37.1. Contreras-Galindo et al. re-
port detection of env transcripts derived from 34 different
HERV-K (HML-2) loci in plasma of 7 HIV-1 patients [44].
This inconsistency might be explained by the use of LC5
cells in our in vitro experiments, where HML-2 transcrip-
tion seems to be generally more restricted than in PBMCs
(Additional file 3, see also ref. [66]), but also in KE37.1
cells, which display a basal HERV-K (HML-2) transcrip-
tion pattern very similar to that of PBMCs of healthy per-
sons, only 6 active loci were detected in persistently
infected cells. However, also technical problems such as
occurrence of genomic DNA from lysed cells in plasma of
patients may influence the examination of blood sam-
ples [67,37]. A modest increase of class II (HERV-K) el-
ements was also detected by Lefebvre et al. in SupT1
cells infected with a VSV-G pseudotyped HIV vector using
SAGE sequencing of the whole transcriptome, but the ob-
tained sequences could not be assigned to specific HERV-K
loci or groups such as HERV-K (HML-2) in this study [68].
There are several possible explanations how HIV-1 infec-
tion may enhance HERV transcription in infected cells.
First it may be a side effect that occurs when HIV-1 impairs
cellular antiretroviral functions [69,70]. Viruses use various
strategies to communicate with host cells and antagonize
cellular restrictions. For example, HIV-1 Vif neutralizes the
cytidine deaminase activity of APOBEC3G, and Vpu and
Nef may counteract Tetherin. There is evidence that APO-
BEC proteins have contributed to hypermutation of HERV-
K (HML-2) elements before they were genetically fixed in
the human genome [71,72]. However, restriction by APO-
BEC3G as well as Tetherin would require de novo repli-
cation of HERVs and reintegration of mutated HERV
sequences, which is highly unlikely.
Contreras-Galindo et al. reported detection of 15 recom-
binant HERV-K (HML-2) transcripts in plasma from 7
HIV-1 infected patients and postulated that these se-
quences are the products of in vivo recombinations
[44]. We also detected some recombinant sequences in all
cell types, where several HERV-K (HML-2) loci are active,
including PBMCs from healthy donors (Additional file 3).
However, these sequences could be easily discriminated
from genuine in vivo recombinants and could be ex-
plained as artifacts generated by ex vivo recombination
during cDNA synthesis and amplification [73]. In vivo re-
combination would require co-packaging of two different
HERV-K (HML-2) transcripts in an infectious HIV-1 par-
ticle followed by re-infection and reverse transcription of
HERV-K (HML-2) RNA by presumably HIV machinery
only then involving template switches. In our opinion, this
would be a very rare event. In previous experiments using
various retroviral vector systems, we have shown that HIV-
1 derived systems co-package almost no HERVs in contrastto particles produced by MLV based packaging cell lines,
which contain considerable amounts of HERV transcripts
[24]. Therefore, we regard activation of HERV transcription
by inhibition of restriction factors requiring re-infection un-
likely and not to explain the substantial increase of HERV
transcripts derived from different class I and II HERV
groups.
Another possibility is the direct or indirect stimulation
of HERV LTR promoters by trans-activating HIV-1 pro-
teins binding to responsive HERV sequences or activat-
ing/inactivating cellular transcription factors. LTRs of
HIV-1 and HERVs share many common features includ-
ing binding sites for host cell factors required for forma-
tion of transcription initiation complexes and sequences
involved in post-transcriptional regulation. For example,
the HIV-1 Rev protein binds to a response element lo-
cated within the HERV-K (HML-2) LTR [32]. Binding
sites for transcription factors such as AP1, SP1, YY1 or
glucocorticoid response elements present in the HIV-1
LTR have been identified in many HERV LTRs (reviewed
in [74]). In particular, HERV-K (HML-2) LTRs have been
extensively examined in silico and numerous potential
transcription factor binding sites and response elements
were detected, albeit in most cases the biological func-
tionality has still to be verified [75].
Our experiments using various siRNAs directed against
HIV-1 transcripts clearly show that HIV-1 gene products
are responsible for up-regulation of at least four different
HERV groups, HERV-T, HERV-E, ERV-9 and HERV-K
(HML-10) in persistently infected LC5 cells. Recently, a re-
combinant HIV-1 Tat protein was reported to increase
HERV-K (HML-2) transcription in Jurkat T-cells and pri-
mary lymphocytes [76]. The authors suggest an involve-
ment of transcription factors NF-κB or NF-AT. Moreover,
stimulation of LTRs from different HERV groups, in par-
ticular HERV-H, HERV-W and HERV-K (HML-4) by the
HTLV-1 Tax protein, another retroviral transactivator with
HIV-1 Tat-like functions, has been demonstrated by co-
transfection of Jurkat T-cells with HERV-LTR-luciferase
constructs and a Tax expressing vector [77]. HIV-1
encoded regulatory proteins like Tat and Nef are known to
activate nuclear factors including NF-κB, NFAT and AP1
and thus stimulate HIV transcription [78,79].
To test the hypothesis of an involvement of cellular
transcription factors in HIV-1 mediated HERV activation
we stimulated Jurkat T-cells to induce a variety of tran-
scription factors including NF-κB, NFAT and AP1 using
agents known to activate HIV-1 expresssion [80]. As ex-
pected, many HERV groups show increased transcript
levels and, moreover, the pattern of activated HERVs in-
cludes all HERV groups activated in de novo and in per-
sistently HIV-1 infected cells. From this data we conclude
that induction of transcription factor expression plays a
crucial role in HIV-1 mediated HERV activation.
Vincendeau et al. Retrovirology  (2015) 12:27 Page 13 of 17Conclusions
In summary, our data demonstrate that productive HIV-
1 infection is associated with alterations of HERV tran-
scription patterns in human cells of different origin.
Activation of HERV transcription is linked to levels of
HIV-1 production in persistently infected cells and may
be abrogated by HIV-1-specific siRNA indicating involve-
ment of HIV-1 gene products in HERV activation. There
are clear differences between HIV-1 activated HERVs in
persistently and in de novo infected cells, suggesting
differential modes of activation. Hence, identification
of persistently HIV-1 infected cells by means of specific-
ally expressed HERV transcripts/proteins as markers may
be of diagnostic value. Furthermore, specific HERV pro-
teins expressed by HIV-1 infected cells could serve as tar-
gets for adjuvant immunotherapies.
Methods
Cell culture
All cells were maintained in Biochrom VLE-RPMI 1640
with stable glutamine and 2.0 g/l NaHCO3 and 10% fetal
calf serum (Seromed, Berlin, Germany). If applicable, 100
U/ml penicillin and 100 μg/ml streptomycin was added to
the culture. Cells were cultured in an H2O-saturated at-
mosphere with 5% CO2 at 37°C. The human epithelia cell
line LC5 is a HeLa derivative [50,81], and LC5-HIV cells
are LC5 cells persistently infected with HIV-1IIIB/LAI
[81]. LC5-RIC is a clonal LC5 cell line expressing a fluor-
escent HIV reporter (DsRed) [55]. The astrocytic cell line
85HG66 was established from a human brain tumor.
TH4-7-5 is a persistently with HIV-1IIIB/LAI infected cell
clone of 85HG66 cells [49]. The human T-lymphoma cell
line KE37.1 and KE37.1-IIIB, the corresponding cell line
persistently infected with HIV-1IIIB/LAI, are described in
[49]. All cell lines were authenticated by the German Col-
lection of Microorganisms and Cell Cultures (DSMZ). For
de novo infection experiments LC5-RIC cells were in-
fected with an HIV-1 patient isolate P-891 [54,55], cul-
tured for three weeks and sorted for HIV positive cells. To
study the time course of HIV-1 infection LC5-RIC cells
were infected with HIV-1IIIB/LAI as described [54,55].
3 days after virus exposure, cells were passaged for the
first time and afterwards every 2–3 days when confluence
reached 100%. Cells were cultured in the presence of se-
lection antibiotics (Hygromycin B, Geneticin) to ensure
ongoing overexpression of CD4 and the HIV-reporter
construct [54,55].
P24-antigen analysis
Quantification of p24 antigen in infected cells was per-
formed using the Coulter HIV-1-p24-Antigen-Assay
(Beckman Coulter) as described previously [82]. 5%
Triton-X was added to the whole-cell extracts and to the
supernatants, centrifuged at 13.000 rpm for 5 minutes atroom temperature and diluted with PBS to a final concen-
tration of 0.5% TritonX. The p24 ELISA was performed
according to the manufacturer’s protocol.
RNA preparation
Total RNA was extracted using a Qiagen RNeasy Mini Kit
according to the manufacturers protocol. To remove gen-
omic DNA contamination, all mRNA samples were treated
with 1 U RNase-free DNase (Promega, Mannheim) per μg
RNA. Subsequently, 25 ng of each mRNA preparation was
tested by PCR with mixed oligo primers (MOP) [47] omit-
ting the reverse transcription step. Only mRNA prepara-
tions negative for amplification products were used for
subsequent reverse transcription and MOP multiplex PCR.
cDNA synthesis and microarray experiments
Reverse transcription of mRNA was performed with 1μg
total RNA using Superscript II (Roche Diagnostics,
Mannheim) according to the manufacturers protocol. Three
independent RNA isolations were used for microarray ana-
lysis. Amplification and labeling of the hybridization probes
by MOP PCR, DNA microarray preparation, hybridization
and post-processing of retrovirus-specific microarrays were
performed as described previously [46,53]. Exclusively arrays
showing reproducible hybridization patterns in triplicate
subarrays were further evaluated. Hybridized microarrays
were scanned using an Affymetrix Scanner GMS 418 (laser
power settings, 100%; gain, 50%), and false color mapping
was used for image visualization.
Quantification of HERV and HIV-1 transcription by
quantitative reverse transcriptase PCR (qRT-PCR)
For amplification of pol (RT) sequences, the following
HERV subgroup-specific pol primers were used for
S71pCRTK-1 (group HERV-T): reverse primer 5’-GTA
CCCCAGGTAGGAAACTCTGGG-3’ , forward primer
5’-CCCCTACCCTTTTTGGGG-3’); E4-1 (group HERV-E):
reverse primer 5’-GCTTTCTTTCTGATCCTAGGCT
GTG-3’, forward primer 5’-CTTTGGGGAGGCGTTG
GCTCGAGACC -3’; ERV-9 (group ERV9): reverse
primer 5’-CCTCAACTGTTTTAATGTCTTAGGGC-
GAGG-3’ , forward primer 5’-CCCTCATCTGTTTGGT-
CAGGCCC-3’); seq59 (group ERV9): reverse primer 5’-
GTGCTGAGGGCCCTGGTTCCTCTGG-3’ , forward pri-
mer 5’- CAGGCACAGGCCCAAGATCTAGTTC-3’; HER
V-KC4 (group HERV-K (HML-10)): reverse primer 5’-
GAATCTCTTCTAATTTGAACCTTTTGAGG-3’, forward
primer 5’-CCCACAGTTTGTCAAACTTTTGTAGGC-3’;
HIV-1: reverse primer 5’-GTTCATAACCCATCCAAAG-
GAATGGAGG-3’, forward primer 5’-CCAAAGTAGCAT-
GACAAAAATC-3’. In general, HERV-specific primers
for quantitative reverse transcriptase PCR (qRT-PCR)
were designed in such a way that for each HERV one
primer matched the capture probe sequences used in
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second primer was located 100 to 150 base pairs upstream
of the first primer [46]. For group HERV-K (HML-2), gag-
specific primers were used for quantification (forward
primer 5’-GGCCATCAGAGTCTAAACCACG-3’, reverse
primer 5’-CTGACTTTCTGGGGGTGGCCG-3’) enabling
a strict discrimination to other HERV-K groups such as
HERV-K (HML-3). HIV-1 transcripts were amplified as
described [83].
qRT-PCR was performed with the Roche LightCycler
1.5 System, using LightCycler FastStart DNA Master
SYBR Green I-Kit and standard LightCycler protocol
(Roche Diagnostics, Mannheim). Cycling conditions
were a 10 minutes denaturation step at 95°C, followed
by 40 cycles of 10 seconds at 95°C, 5 seconds at 60°C,
and 10 seconds at 72°C. RNA-Polymerase II (RPII) tran-
scripts were analyzed as internal standard, using primers
given in [84]. To confirm that specific products were
amplified, the PCRs were further analyzed by melting
curve analysis and by agarose gel electrophoresis. ΔCT-
values were calculated as follows: CT (gene of interest) -
CT (house keeping gene). The relative transcription was
calculated by the 2-ΔΔCT method [85]. Furthermore, ex-
tensive standardization of PCR reactions was initially
performed through melting curve analysis of respective
amplicons in order to minimize primer pair formation
(data not shown). Absolute quantification of HIV pro-
viral copies was performed as described previously [82].
RNA interference
For down-regulation of HIV-1 gene expression, HIV-1-
specific silencing RNAs (siRNA) [56] and non-silencing
control RNAs (sin.s.) were synthesized (Qiagen). Trans-
fections were carried out using RNAiFect transfection
reagent (Qiagen) according to the manufacturer’s proto-
col. The day before transfection, 1 × 105 target cells were
seeded per well of a 12-well plate. 2 μg siRNA per well
was used for each transfection. After 24 hours, medium
was removed, cells were washed with PBS and new
medium was added. Gene silencing was monitored by
p24 analysis of the supernatant 72 hours after transfection.
Total RNA of siRNA treated cells was extracted using a
Qiagen RNeasy Mini Kit, reverse transcribed using the
Superscript II Kit, and analyzed for HERV transcription
using qRT-PCR.
Amplification, cloning, and sequence analysis of HML-2
and HML-3 transcripts
For amplification of HML-2 transcripts, PCR was performed
using 2 μl of undiluted cDNA. HERV-K (HML-2)-specific
primers gag_plus (5’-GGCCATCAGAGTCTAAACCACG-
3’) and gag_minus (5’-GCAGCCCTATTTCTTCGGACC-
3’) were used to generate gag gene derived PCR products
[58,86]. For amplification of the more divergent HERV-K(HML-3) env genes a multiplex PCR was carried out
using the following primer combinations: HML3FOR (5’-
TGTCGAGACTGATGCTGAGG-3’), HML3FOR_a (5’-T
GTCAAGACTGACTCTGTGG-3’), HML3FOR_b (5’-TG
TTGAGACTGATGCTGAGA-3’), HML3FOR_c (5’-TGT
TGAGACTGACACTGAGA-3’) and HML3REV (5’- AAT
GATATGGCCCGCTGTAG-3’), HML3REV_a (5’- AATG
ATATGGGTTGTTGTAG-3’), HML3REV_b (5’- AATAA
TATGGCCTGCTGTAG-3’), HML3REV_c (5’-TATGA-
TATGGCCCGCTGTAG-3’), HML3REV_d (5’- CATGAT
ATGGCCCGCTCTAG-3’), HML3REV_e (5’-GATGA-
TATGCCTGCTGTAG-3’), HML3REV_f (5’- CTAGAGC
AGGCCATATCAGT-3’). The 50 μl PCR mix contained
1× Expand High Fidelity buffer with MgCl2, 0.2 μM deox-
ynucleotides, and 2.6 U expand High Fidelity enzyme mix
(Roche Diagnostics, Mannheim). PCR conditions were as
follows: initial denaturation at 94°C for 5 minutes; 40 cy-
cles at 94°C for 1 minutes, annealing at 57°C for 45 sec-
onds, and elongation at 72°C for 1 minutes, followed by
a final elongation step at 72°C for 10 minutes. HML-2-
specific gag PCR products were purified (NucleoSpin Ex-
tract II, Macherey-Nagel, Düren), cloned into the pGEM
T-Easy vector (Promega) and used to transform TOP10F
bacterial cells. Plasmid DNA was isolated from insert-
containing colonies according to the manufacturer’s
protocol (NucleoSpin Plasmid, Macherey-Nagel, Düren).
Subsequently, cloned HML-2 cDNAs were analyzed by
Sanger sequencing using an Applied Biosystems 3730 ×
Capillary Sequencer (Seq-IT, Kaiserslautern, Germany).
We mapped individual cDNA sequences to their respect-
ive genomic loci in the March 2006 (NCBI36/hg18) ver-
sion of the human genome sequence by using BLAT at the
Human Genome Browser, as described previously [58,86].
Stimulation of Jurkat T-cells with PMA/ionomycin and
CD3/CD28 antibodies
2 × 106 Jurkat T-cells were incubated with phorbol-12-
myristate-13-acetate (PMA) and ionomycin or with anti-
bodies against CD3 and CD28 in conditional complete
RPMI medium [60]. For stimulation with PMA/ionomycin
200 ng/ml PMA and 300 ng/ml ionomycin were added
directly to the medium (1 ml) and cells were incubated for
3 hours. For stimulation through CD3/CD28 antibody
ligation the following antibodies were used to stimulate
2 × 106 cells in 300 μl medium: 1 μg/ml anti-hCD3
(IgG2a), 5 μg/ml anti-hCD28 (IgG1), 2.5 μg/ml anti IgG1,
and 2.5 μg/ml anti IgG2a. After 3 hours cells were placed
on ice, washed once with cold PBS and RNA was isolated.
Additional files
Additional file 1: Down-regulation of HIV-1 transcription by specific
siRNAs. (A) Binding sites of HIV-1-specific siRNAs used for down-regulation
of HIV-1. (B) HIV-1 transcription in LC5-HIV cells treated with HIV-1 specific
Vincendeau et al. Retrovirology  (2015) 12:27 Page 15 of 17siRNAs. The Y-axis shows the x-fold relative HIV-1 transcript levels in LC5-HIV
cells transfected with non-silencing siRNA (sin.s.) and HIV-1-specific siRNAs
(sigag, sitat/rev, sinef, sienv) referred to uninfected control cells. Relative
transcription was quantified according [85] and normalized to RPII transcript
levels. The standard error for triplicate experiments is indicated in each bar.
Additional file 2: Influence of overexpressed Risp proteins on
HERV activity in persistently HIV-1 infected LC5 cells examined by a
retrovirus-specific microarray False color mapping was used for image
visualization. The house keeping genes ubiquitin, glycerinaldehyde-3-
phosphate-dehydrogenase (GAPDH) and hypoxanthine-guanine
phosphoribosyltransferase (HPRT) served as a quality control and consequently
as an internal standard. HIV-1 oligonucleotides are also spotted on the chip as a
positive control for the infected cells and to demonstrate downregulation of
HIV-1 transcription in cells overexpressing Risp. HERVs are grouped in class I, II
and III elements. It should be noted that each positive spot on the microarray
can represent multiple HERV proviruses of one multicopy HERV subgroup with
sufficient sequence similarity that individual elements cannot be distinguished.
HERV subgroups found up-regulated in all HIV-1 infected cell lines (see Figure 2)
are displayed with red letters.
Additional file 3: HERV-K (HML-2) transcription in PBMCs of six
healthy individuals.
Additional file 4: Provirus copy numbers of LC5-RIC cells infected
with HIV1IIIB/LAI. Relative transcription was quantified according to [85]
and normalized to RPII transcript levels.
Additional file 5: HERV-K (HML-3) transcription in de novo and
persistently infected LC5 cells.
Additional file 6: Relative transcription of IL-2 in PMA/ionomycin or
CD3/CD28 stimulated Jurkat T-cells. The Y-axis shows the x-fold relative
transcription of IL-2 after PMA/ionomycin or CD3/CD28 stimulation referred
to unstimulated cells. Relative transcription was quantified according to
[85] and normalized to RPII transcript levels. Mean values and standard
deviations are indicated for triplicate experiments performed with three
independent RNA isolations.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
Conceived and designed the experiments: MV, JM, ADG, SK, WS, KH, RB-W,
CL-M; performed the experiments: MV, IG, JMHS, AN, MH, SK, KH; analyzed
and interpreted the data: MV, IG, JMHS, AN, JM, ADG, MH, WS, KH, RB-W,
CL-M; wrote the manuscript: MV, JM, RB-W, CL-M. All authors have read and
approved the final manuscript.Acknowledgements
We thank Ulrike Protzer for continuous support and encouragement and
Ingrid Hülsmeyer, Ute Finkel and Johanna Götz for expert technical
assistance.
Author details
1Institute of Virology, Helmholtz Zentrum München, German Research Center
for Environmental Health, Neuherberg, Germany. 2Research Unit Cellular
Signal Integration, Institute of Molecular Toxicology and Pharmacology,
Helmholtz Zentrum München, German Research Center for Environmental
Health, Neuherberg, Germany. 3Department of Hematology and Oncology,
University Hospital Mannheim, University of Heidelberg, Mannheim,
Germany. 4Department of Human Genetics, Center of Human and Molecular
Biology, Medical Faculty, University of Saarland, Homburg, Germany.
5Department of Wildlife Diseases, Leibniz Institute for Zoo and Wildlife
Research, Berlin, Germany. 6Assay Development and Screening Platform,
Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum
München, German Research Center for Environmental Health, Neuherberg,
Germany.
Received: 5 June 2014 Accepted: 5 March 2015References
1. Sverdlov E. Retroviruses and primate genome evolution. Georgetown, Texas,
USA: Landes Bioscience; 2005.
2. Belshaw R, Katzourakis A, Paces J, Burt A, Tristem M. High copy number in
human endogenous retrovirus families is associated with copying
mechanisms in addition to reinfection. Mol Biol Evol. 2005;22:814–7.
3. Belshaw R, Pereira V, Katzourakis A, Talbot G, Paces J, Burt A, et al.
Long-term reinfection of the human genome by endogenous
retroviruses. Proc Natl Acad Sci U S A. 2004;101:4894–9.
4. Mager DL, Medstrand P. Retroviral repeat sequences. In: Cooper D, editor.
Nature encyclopedia of the human genome. D. Cooper edition. London,
United Kingdom: Nature Publishing Group; 2003. p. 57–63.
5. Evans LH, Alamgir AS, Owens N, Weber N, Virtaneva K, Barbian K, et al.
Mobilization of endogenous retroviruses in mice after infection with an
exogenous retrovirus. J Virol. 2009;83:2429–35.
6. Dewannieux M, Harper F, Richaud A, Letzelter C, Ribet D, Pierron G, et al.
Identification of an infectious progenitor for the multiple-copy HERV-K
human endogenous retroelements. Genome Res. 2006;16:1548–56.
7. Lee YN, Bieniasz PD. Reconstitution of an infectious human endogenous
retrovirus. PLoS Pathog. 2007;3:e10.
8. Heslin DJ, Murcia P, Arnaud F, Van Doorslaer K, Palmarini M, Lenz J. A single
amino acid substitution in a segment of the CA protein within Gag that has
similarity to human immunodeficiency virus type 1 blocks infectivity of a
human endogenous retrovirus K provirus in the human genome. J Virol.
2009;83:1105–14.
9. de Parseval N, Lazar V, Casella JF, Benit L, Heidmann T. Survey of human
genes of retroviral origin: identification and transcriptome of the genes
with coding capacity for complete envelope proteins. J Virol.
2003;77:10414–22.
10. Jern P, Sperber GO, Blomberg J. Use of endogenous retroviral sequences
(ERVs) and structural markers for retroviral phylogenetic inference and
taxonomy. Retrovirology. 2005;2:50.
11. Galli UM, Sauter M, Lecher B, Maurer S, Herbst H, Roemer K, et al. Human
endogenous retrovirus rec interferes with germ cell development in mice
and may cause carcinoma in situ, the predecessor lesion of germ cell
tumors. Oncogene. 2005;24:3223–8.
12. Denne M, Sauter M, Armbruester V, Licht JD, Roemer K, Mueller-Lantzsch N.
Physical and functional interactions of human endogenous retrovirus
proteins Np9 and rec with the promyelocytic leukemia zinc finger protein.
J Virol. 2007;81:5607–16.
13. Ruprecht K, Mayer J, Sauter M, Roemer K, Mueller-Lantzsch N. Endogenous
retroviruses and cancer. Cell Mol Life Sci. 2008;65:3366–82.
14. Bannert N, Kurth R. Retroelements and the human genome: new perspectives
on an old relation. Proc Natl Acad Sci U S A. 2004;101 Suppl 2:14572–9.
15. Perron H, Lazarini F, Ruprecht K, Pechoux-Longin C, Seilhean D, Sazdovitch
V, et al. Human endogenous retrovirus (HERV)-W ENV and GAG proteins:
physiological expression in human brain and pathophysiological modulation
in multiple sclerosis lesions. J Neurovirol. 2005;11:23–33.
16. Balada E, Ordi-Ros J, Vilardell-Tarres M. Molecular mechanisms mediated by
human endogenous retroviruses (HERVs) in autoimmunity. Rev Med Virol.
2009;19:273–86.
17. Hohenadl C, Germaier H, Walchner M, Hagenhofer M, Herrmann M, Sturzl
M, et al. Transcriptional activation of endogenous retroviral sequences in
human epidermal keratinocytes by UVB irradiation. J Invest Dermatol.
1999;113:587–94.
18. Kelleher CA, Wilkinson DA, Freeman JD, Mager DL, Gelfand EW. Expression
of novel-transposon-containing mRNAs in human T cells. J Gen Virol.
1996;77:1101–10.
19. Stengel S, Fiebig U, Kurth R, Denner J. Regulation of human endogenous
retrovirus-K expression in melanomas by CpG methylation. Genes
Chromosomes Cancer. 2010;49:401–11.
20. Frank O, Jones-Brando L, Leib-Mösch C, Yolken R, Seifarth W. Altered
transcriptional activity of human endogenous retroviruses in neuroepithelial
cells after infection with Toxoplasma gondii. J Infect Dis. 2006;194:1447–9.
21. Nellaker C, Yao Y, Jones-Brando L, Mallet F, Yolken RH, Karlsson H. Transactivation
of elements in the human endogenous retrovirus W family by viral infection.
Retrovirology. 2006;3:44.
22. Ruprecht K, Obojes K, Wengel V, Gronen F, Kim KS, Perron H, et al.
Regulation of human endogenous retrovirus W protein expression by
herpes simplex virus type 1: implications for multiple sclerosis. J Neurovirol.
2006;12:65–71.
Vincendeau et al. Retrovirology  (2015) 12:27 Page 16 of 1723. Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT. Epstein-Barr virus
transactivates the human endogenous retrovirus HERV-K18 that encodes a
superantigen. Immunity. 2001;15:579–89.
24. Zeilfelder U, Frank O, Sparacio S, Schön U, Bosch V, Seifarth W, et al. The
potential of retroviral vectors to cotransfer human endogenous retroviruses
(HERVs) from human packaging cell lines. Gene. 2007;390:175–9.
25. Hsiao FC, Lin M, Tai A, Chen G, Huber BT. Cutting edge: epstein-barr virus
transactivates the HERV-K18 superantigen by docking to the human complement
receptor 2 (CD21) on primary B cells. J Immunol. 2006;177:2056–60.
26. Hsiao FC, Tai AK, Deglon A, Sutkowski N, Longnecker R, Huber BT. EBV
LMP-2A employs a novel mechanism to transactivate the HERV-K18
superantigen through its ITAM. Virology. 2009;385:261–6.
27. Sutkowski N, Chen G, Calderon G, Huber BT. Epstein-Barr virus latent
membrane protein LMP-2A is sufficient for transactivation of the human
endogenous retrovirus HERV-K18 superantigen. J Virol. 2004;78:7852–60.
28. Tai AK, Luka J, Ablashi D, Huber BT. HHV-6A infection induces expression of
HERV-K18-encoded superantigen. J Clin Virol. 2009;46:47–8.
29. Turcanova VL, Bundgaard B, Hollsberg P. Human herpesvirus-6B induces
expression of the human endogenous retrovirus K18-encoded superantigen.
J Clin Virol. 2009;46:15–9.
30. Assinger A, Yaiw KC, Gottesdorfer I, Leib-Mösch C, Soderberg-Naucler C.
Human cytomegalovirus (HCMV) induces human endogenous retrovirus
(HERV) transcription. Retrovirology. 2013;10:132.
31. van der Kuyl AC. HIV infection and HERV expression: a review. Retrovirology.
2012;9:6.
32. Magin C, Löwer R, Löwer J. cORF and RcRE, the Rev/Rex and RRE/RxRE
homologues of the human endogenous retrovirus family HTDV/HERV-K.
J Virol. 1999;73:9496–507.
33. Magin-Lachmann C, Hahn S, Strobel H, Held U, Löwer J, Löwer R. Rec
(formerly Corf) function requires interaction with a complex, folded RNA
structure within its responsive element rather than binding to a discrete
specific binding site. J Virol. 2001;75:10359–71.
34. Yang J, Bogerd HP, Peng S, Wiegand H, Truant R, Cullen BR. An ancient
family of human endogenous retroviruses encodes a functional homolog
of the HIV-1 Rev protein. Proc Natl Acad Sci U S A. 1999;96:13404–8.
35. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, et al.
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase
activity. Curr Biol. 2005;15:166–70.
36. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is
degraded by the proteasome in response to HIV-1 Vif. Nat Med.
2003;9:1404–7.
37. Laderoute MP, Giulivi A, Larocque L, Bellfoy D, Hou Y, Wu HX, et al. The
replicative activity of human endogenous retrovirus K102 (HERV-K102) with
HIV viremia. Aids. 2007;21:2417–24.
38. Garrison KE, Jones RB, Meiklejohn DA, Anwar N, Ndhlovu LC, Chapman JM,
et al. T cell responses to human endogenous retroviruses in HIV-1 infection.
PLoS Pathog. 2007;3:e165.
39. SenGupta D, Tandon R, Vieira RG, Ndhlovu LC, Lown-Hecht R, Ormsby
CE, et al. Strong human endogenous retrovirus-specific T cell responses
are associated with control of HIV-1 in chronic infection. J Virol.
2011;85:6977–85.
40. Tandon R, Sengupta D, Ndhlovu LC, Vieira RG, Jones RB, York VA, et al.
Identification of human endogenous retrovirus (HERV)-specific T cell
responses in vertically HIV-1-infected subjects. J Virol. 2011;85:11526–31.
41. Jones RB, John VM, Hunter DV, Martin E, Mujib S, Mihajlovic V, et al. Human
endogenous retrovirus K (HML-2) Gag- and Env-specific T-cell responses are
infrequently detected in HIV-1-infected subjects using standard peptide
matrix-based screening. Clin Vaccine Immunol. 2012;19:288–92.
42. Contreras-Galindo R, Kaplan MH, Markovitz DM, Lorenzo E, Yamamura Y.
Detection of HERV-K (HML-2) viral RNA in plasma of HIV type 1-infected
individuals. AIDS Res Hum Retroviruses. 2006;22:979–84.
43. Contreras-Galindo R, Almodovar-Camacho S, Gonzalez-Ramirez S, Lorenzo E,
Yamamura Y. Comparative longitudinal studies of HERV-K and HIV-1 RNA
titers in HIV-1-infected patients receiving successful versus unsuccessful
highly active antiretroviral therapy. AIDS Res Hum Retroviruses.
2007;23:1083–6.
44. Contreras-Galindo RA, Kaplan MH, Contreras-Galindo AC, Gonzalez-Hernandez
M, Ferlengui I, Giusti F, et al. Characterization of human endogenous retroviral
elements in the blood of HIV-1-infected individuals. J Virol. 2012;86:262–76.
45. Bhardwaj N, Maldarelli F, Mellors J, Coffin JM. HIV-1 infection leads to
increased transcription of human endogenous retrovirus HERV-K (HML-2)proviruses in vivo but not to increased virion production. J Virol.
2014;88:11108–20.
46. Seifarth W, Frank O, Zeilfelder U, Spiess B, Greenwood AD, Hehlmann R,
et al. Comprehensive analysis of human endogenous retrovirus
transcriptional activity in human tissues with a retrovirus-specific microarray.
J Virol. 2005;79:341–52.
47. Seifarth W, Spiess B, Zeilfelder U, Speth C, Hehlmann R, Leib-Mösch C.
Assessment of retroviral activity using a universal retrovirus chip. J Virol
Methods. 2003;112:79–91.
48. Seifarth W, Frank O, Schreml J, Leib-Mösch C. RetroArray – a comprehensive
diagnostic DNA chip for rapid detection and identification of retroviruses,
retroviral contaminants, and mistaken identity of cell lines. In: Duncan SJ,
Duncan SJ, Wiley PH, editors. Encyclopedia of DNA Research. New York:
Nova Science Publishers, Inc; 2011.
49. Brack-Werner R, Kleinschmidt A, Ludvigsen A, Mellert W, Neumann M,
Herrmann R, et al. Infection of human brain cells by HIV-1: restricted virus
production in chronically infected human glial cell lines. AIDS. 1992;6:273–85.
50. Schön U, Diem O, Leitner L, Gunzburg WH, Mager DL, Salmons B, et al.
Human endogenous retroviral long terminal repeat sequences as cell
type-specific promoters in retroviral vectors. J Virol. 2009;83:12643–50.
51. Frank O, Verbeke C, Schwarz N, Mayer J, Fabarius A, Hehlmann R, et al.
Variable transcriptional activity of endogenous retroviruses in human breast
cancer. J Virol. 2008;82:1808–18.
52. Jurka J, Kapitonov VV, Pavlicek A, Klonowski P, Kohany O, Walichiewicz J.
Repbase update, a database of eukaryotic repetitive elements. Cytogenet
Genome Res. 2005;110:462–7.
53. Frank O, Giehl M, Zheng C, Hehlmann R, Leib-Mösch C, Seifarth W. Human
endogenous retrovirus expression profiles in samples from brains of patients
with schizophrenia and bipolar disorders. J Virol. 2005;79:10890–901.
54. Helfer M, Koppensteiner H, Schneider M, Rebensburg S, Forcisi S, Muller C,
et al. The root extract of the medicinal plant Pelargonium sidoides is a
potent HIV-1 attachment inhibitor. PLoS One. 2014;9:e87487.
55. Kremb S, Helfer M, Heller W, Hoffmann D, Wolff H, Kleinschmidt A, et al.
EASY-HIT: HIV full-replication technology for broad discovery of multiple
classes of HIV inhibitors. Antimicrob Agents Chemother. 2010;54:5257–68.
56. Ter Brake O, Berkhout B. A novel approach for inhibition of HIV-1 by RNA
interference: counteracting viral escape with a second generation of siRNAs.
J RNAi Gene Silenc: Int J RNA and Gene Targeting Res. 2005;1:56–65.
57. Vincendeau M, Kramer S, Hadian K, Rothenaigner I, Bell J, Hauck SM, et al.
Control of HIV replication in astrocytes by a family of highly conserved
host proteins with a common Rev-interacting domain (Risp). AIDS.
2010;24:2433–42.
58. Flockerzi A, Ruggieri A, Frank O, Sauter M, Maldener E, Kopper B, et al.
Expression patterns of transcribed human endogenous retrovirus HERV-K
(HML-2) loci in human tissues and the need for a HERV Transcriptome
Project. BMC Genomics. 2008;9:354.
59. Mayer J, Sauter M, Racz A, Scherer D, Mueller-Lantzsch N, Meese E. An
almost-intact human endogenous retrovirus K on human chromosome 7.
Nat Genet. 1999;21:257–8.
60. Scharschmidt E, Wegener E, Heissmeyer V, Rao A, Krappmann D.
Degradation of Bcl10 induced by T-cell activation negatively regulates
NF-kappa B signaling. Mol Cell Biol. 2004;24:3860–73.
61. Boulassel MR, Chomont N, Pai NP, Gilmore N, Sekaly RP, Routy JP. CD4 T
cell nadir independently predicts the magnitude of the HIV reservoir
after prolonged suppressive antiretroviral therapy. J Clin Virol.
2012;53:29–32.
62. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B,
et al. HIV reservoir size and persistence are driven by T cell survival and
homeostatic proliferation. Nat Med. 2009;15:893–900.
63. Medstrand P, Lindeskog M, Blomberg J. Expression of human endogenous
retroviral sequences in peripheral blood mononuclear cells of healthy
individuals. J Gen Virol. 1992;73:2463–6.
64. Willer A, Saussele S, Gimbel W, Seifarth W, Kister P, Leib-Mösch C, et al. Two
groups of endogenous MMTV related retroviral env transcripts expressed in
human tissues. Virus Genes. 1997;15:123–33.
65. Sugimoto J, Matsuura N, Kinjo Y, Takasu N, Oda T, Jinno Y. Transcriptionally
active HERV-K genes: identification, isolation, and chromosomal mapping.
Genomics. 2001;72:137–44.
66. Brinzevich D, Young GR, Sebra R, Ayllon J, Maio SM, Deikus G, et al. HIV-1
interacts with human endogenous retrovirus K (HML-2) envelopes derived
from human primary lymphocytes. J Virol. 2014;88:6213–23.
Vincendeau et al. Retrovirology  (2015) 12:27 Page 17 of 1767. Esqueda D, Xu F, Moore Y, Yang Z, Huang G, Lennon PA, et al. Lack of
correlation between HERV-K expression and HIV-1 viral load in plasma
specimens. Ann Clin Lab Sci. 2013;43:122–5.
68. Lefebvre G, Desfarges S, Uyttebroeck F, Munoz M, Beerenwinkel N, Rougemont
J, et al. Analysis of HIV-1 expression level and sense of transcription by
high-throughput sequencing of the infected cell. J Virol. 2011;85:6205–11.
69. Malim MH, Bieniasz PD. HIV Restriction Factors and Mechanisms of Evasion.
Cold Spring Harb Perspect Med. 2012;2:a006940.
70. Wolf D, Goff SP. Host restriction factors blocking retroviral replication.
Annu Rev Genet. 2008;42:143–63.
71. Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, Bishop KN,
et al. Conserved footprints of APOBEC3G on Hypermutated human
immunodeficiency virus type 1 and human endogenous retrovirus HERV-K
(HML2) sequences. J Virol. 2008;82:8743–61.
72. Lee YN, Malim MH, Bieniasz PD. Hypermutation of an ancient human
retrovirus by APOBEC3G. J Virol. 2008;82:8762–70.
73. Flockerzi A, Maydt J, Frank O, Ruggieri A, Maldener E, Seifarth W, et al.
Expression pattern analysis of transcribed HERV sequences is complicated
by ex vivo recombination. Retrovirology. 2007;4:39.
74. Leib-Mösch C, Seifarth W, Schön U. Influence of human endogenous
retroviruses on cellular gene expression. In: Sverdlov ED, editor. Retroviruses
and primate evolution. Georgetown, Texas, USA: Landes Bioscience; 2005.
75. Manghera M, Douville RN. Endogenous retrovirus-K promoter: a landing
strip for inflammatory transcription factors? Retrovirology. 2013;10:16.
76. Gonzalez-Hernandez MJ, Swanson MD, Contreras-Galindo R, Cookinham S,
King SR, Noel Jr RJ, et al. Expression of human endogenous retrovirus type
K (HML-2) is activated by the Tat protein of HIV-1. J Virol. 2012;86:7790–805.
77. Toufaily C, Landry S, Leib-Mösch C, Rassart E, Barbeau B. Activation of LTRs
from different human endogenous retrovirus (HERV) families by the HTLV-1
tax protein and T-cell activators. Viruses. 2011;3:2146–59.
78. Fortin JF, Barat C, Beausejour Y, Barbeau B, Tremblay MJ. Hyper-responsiveness
to stimulation of human immunodeficiency virus-infected CD4+ T cells
requires Nef and Tat virus gene products and results from higher NFAT,
NF-kappaB, and AP-1 induction. J Biol Chem. 2004;279:39520–31.
79. Fiume G, Vecchio E, De Laurentiis A, Trimboli F, Palmieri C, Pisano A, et al.
Human immunodeficiency virus-1 Tat activates NF-kappaB via physical
interaction with IkappaB-alpha and p65. Nucleic Acids Res. 2012;40:3548–62.
80. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, et al.
An in-depth comparison of latent HIV-1 reactivation in multiple cell model
systems and resting CD4+ T cells from aviremic patients. PLoS Pathog.
2013;9:e1003834.
81. Mellert W, Kleinschmidt A, Schmidt J, Festl H, Emler S, Roth WK, et al.
Infection of human fibroblasts and osteoblast-like cells with HIV-1. Aids.
1990;4:527–35.
82. Rothenaigner I, Kramer S, Ziegler M, Wolff H, Kleinschmidt A, Brack-Werner
R. Long-term HIV-1 infection of neural progenitor populations. AIDS.
2007;21:2271–81.
83. Vincendeau M, Nagel D, Brenke JK, Brack-Werner R, Hadian K. Heterogenous
nuclear ribonucleoprotein Q increases protein expression from HIV-1
Rev-dependent transcripts. Virol J. 2013;10:151.
84. Radonic A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to
reference gene selection for quantitative real-time PCR. Biochem Biophys
Res Commun. 2004;313:856–62.
85. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2 (−Delta Delta C (T)) Method. Methods.
2001;25:402–8.
86. Laufer G, Mayer J, Mueller BF, Mueller-Lantzsch N, Ruprecht K. Analysis of
transcribed human endogenous retrovirus W env loci clarifies the origin of
multiple sclerosis-associated retrovirus env sequences. Retrovirology.
2009;6:37.
87. Mayer J, Blomberg J, Seal RL. A revised nomenclature for transcribed human
endogenous retroviral loci. Mob DNA. 2011;2:7.
88. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The
human genome browser at UCSC. Genome Res. 2002;12:996–1006.
89. Subramanian RP, Wildschutte JH, Russo C, Coffin JM. Identification,
characterization, and comparative genomic distribution of the HERV-K
(HML-2) group of human endogenous retroviruses. Retrovirology. 2011;8:90.
90. Mayer J, Stuhr T, Reus K, Maldener E, Kitova M, Asmus F, et al. Haplotype
analysis of the human endogenous retrovirus locus HERV-K (HML-2. HOM)
and its evolutionary implications. J Mol Evol. 2005;61:706–15.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
